In order to provide you with relevant and meaningful content we need to know more about you.
Please choose the category that best describes you.
This content is intended for U.S. Healthcare Professionals. Would you like to proceed?
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
DILANTIN is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures.
FOR ORAL ADMINISTRATION ONLY; NOT FOR PARENTERAL USE
A calibrated measuring device is...
DILANTIN-125 is available as a 125 mg phenytoin/5 mL oral suspension of orange color with an orange-vanilla flavor.
DILANTIN is contraindicated in patients with:
Abrupt withdrawal of phenytoin in epileptic patients may precipitate status...
The following serious adverse reactions are described elsewhere in the labeling:
Phenytoin is extensively bound to plasma proteins and is prone to competitive displacement. Phenytoin is primarily metabolized by the hepatic cytochrome P450 enzyme CYP2C9 and to a lesser extent by...
Pregnancy Exposure Registry
The lethal dose in pediatric patients is not known. The lethal dose in adults is estimated to be 2 to 5 grams. The initial symptoms are nystagmus, ataxia, and dysarthria. Other signs are tremor, hyperreflexia,...
DILANTIN (phenytoin) is related to the barbiturates in chemical structure, but has a five-membered ring. The chemical name is 5,5-diphenyl-2,4 imidazolidinedione, having the following structural formula:
The precise mechanism by which phenytoin exerts its therapeutic effect has not been established but is thought to...
DILANTIN-125 Oral Suspension is supplied as follows:
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at https://vaers.hhs.gov or call (800) 822-7967.